On January 6, Glory Exchange reported that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as "Yichang Humanwell", in which the company holds 80% of the shares), recently received the "Drug Registration Certificate" for Celecoxib Capsules issued by the National Medical Products Administration.
The approved indications for Celecoxib Capsules are: (1) for the relief of symptoms and signs of osteoarthritis (OA); (2) for the relief of symptoms and signs of adult rheumatoid arthritis (RA); (3) for the treatment of adult acute pain (AP); (4) for the relief of symptoms and signs of ankylosing spondylitis.
